Titan Energy Worldwide (OTC: TEWI) is a provider of onsite power generation, energy management and energy efficiency products and services that help support and improve the performance of our nation's electrical utility grid. We operate in an area of the overall electrical utility infrastructure called Distributed Generation, whereby we specialize in the deployment of power generation equipment at the consumer's facility and the integration of that equipment through monitoring and communication systems with the needs of the utility's electrical grid.
The company has announced that it has booked “more than $2 million in purchase orders for onsite power generation equipment in the month of January 2012, a record month for new orders. Included in these equipment bookings was an order from Titan's New York office for $1.2 million from a new national account. The New York office booked more than $1.5 million in new orders in the month of January.”
Cliff Macaylo, President of Northeast Operations for Titan Energy Worldwide, commented,
"We have succeeded in winning the first of what we hope to be many new equipment sales contracts with a major national energy company. This new order represents four generators totaling 5.5 megawatts to support one of dozens of locations for this client across the country. We were able to demonstrate that we could deliver a superior product at a competitive price and do so in a timely manner. This also demonstrated that we can complete and deliver on a national basis. We hope this opens the door to additional orders in the near future."
Titan posted approximately $10 million in equipment sales in 2011. The company is on pace to exceed 2011 equipment sales figures, according to current bookings and backlog.
Jeffrey Flannery, Chief Executive Officer of Titan Energy Worldwide, added,
"It is still early in the year, but we have accumulated a significant backlog of equipment projects which combined with an increase in new orders points to a strong 2012. Our sales team in New York in particular has unlocked a significant number of new opportunities that I expect to result in strong sales in the first and second quarters of this year.”
Read more at VirtualPressOffice.com.
ProActive Capital Indexes
See ProActive's Disclaimer
Stratus Media Group, Inc. (OTCBB: SMDI; Twitter: $SMDI) is an owner, producer, promoter and operator of live entertainment events that generate revenue through corporate sponsorships, ticket sales, corporate hospitality, event merchandise and concessions. Stratus also provides athlete management, representation and endorsements. Headquartered in Santa Barbara, California, with offices in Los Angeles, California; New York City, New York; Geneva, Switzerland; and Perugia, Italy, the company also owns Stratus Rewards Visa White Card, an ultra-exclusive consumer rewards marketing and redemption program, providing premium redemption benefits to members in the form of VIP event access, luxury trips, private jet travel, luxury automobiles, high-end merchandise and other rewards.
Stratus launched its 2012 live event calendar with an action packed MMA fight card on January 21 with “ProElite presents: Da Spyder vs. Minowaman” at the Neal Blaisdell Center in Honolulu.
The main event featured the rugged Hawiian Kendall ‘Da Spyder’ Grove (13-9) "taking on the long-awaited North American debut of Japanese and international fan favorite Ikuhisa ‘Minowaman’ Minowa (51-32-8)." The co-main event "featured Olympic silver medalist and #9 world-ranked Sara McMann (4-0) against #5 ranked Hitomi ‘Girlfight Monster’ Akano (18-8), also from Japan." See all fight results at ProElite.com.
In an interview with Michael Schiavello "The Voice", Paul Feller, President and CEO of Stratus Media Group and Chairman of ProElite, expressed his excitement about the MMA fights, the direction of the company, and what to expect from 2012:
ProActive Capital Indexes
See ProActive's Disclaimer
CytoSorbents Corporation (OTCBB: CTSO) is a critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb™, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in cases where cytokines are elevated.
The company presented at the One Med Forum in San Francisco, which ran from January 9 through 12th, 2012. Company CEO Dr. Phillip Chan gave the presentation included below.
Cytosorbents OneMedPlace Presentation 2012
ProActive Capital Indexes
See ProActive's Disclaimer
Onstream Media Corporation (Nasdaq: ONSM) is a leading online service provider of live and on-demand Internet broadcasting, corporate web communications and virtual marketplace technology. Onstream Media's innovative Digital Media Services Platform (DMSP) provides customers with cost effective tools for encoding, managing, indexing, and publishing content via the Internet.
The company has announced that "Links Marketing Group Inc., a leading golf magazine publisher and TTG Media Inc., a golf industry marketing company that creates over 500,000 golf course guides annually, have formed a joint partnership (Golf Industry 365) and signed a MarketPlace365® services agreement to develop The Golf Buying Show. Links Marketing and TTG Media expect to bring together thousands of members, business partners and golf enthusiasts into a new, multimedia online environment that is 100% accessible to interested parties all over the world."
"With the golf industry seeing a decline in attendance at major golf shows, the opportunity to provide a virtual meeting spot for golf enthusiasts and merchandisers presents a real boost for our combined marketing efforts," says Randy McDonald, President of Links Marketing. "The overall costs can be greatly reduced through the use of such innovative technology, which really brings the game into the modern era in a user-friendly, online environment that will be extremely appealing to golfers, manufacturers and advertisers alike."
"For an industry like golf, and sports in general, this is the perfect marriage of technology and marketing. The downturn in attendance at physical trade shows all over the world can be instantly moved in the other direction, with the ability of manufacturers, customers, avid golfers and related marketing partners to all meet in one spot, with no associated travel fees or the inconvenience of flying to another part of the country," added Randy Selman, President and CEO of Onstream Media. "We are very enthusiastic about the opportunity provided with this cross-pollination of so many diverse customers and industries, including food & beverage, hospitality, manufacturers and associated advertising and marketing."
Read the full release on 4-traders.com.
ProActive Capital Indexes
See ProActive's Disclaimer
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
According to PR-Inside.com, "the biotechnology industry has performed well in the early stages of 2012. The iShares NASDAQ Biotechnology Index is presently up nearly eight percent month-on-month as the industry continues to recover nicely from the global economic crisis. According to a recent report from Global Industry Analysts, Inc. (GIA) the improving economic conditions have led to an increase in funding for the biotechnology industry."
GIA predicts the Global Biotechnology Market to exceed "US$320 Billion by 2015, as increased availability of funding for R&D, expanding use of biotechnology in agriculture and medical sciences, and favorable government initiatives are expected to drive growth in the biotechnology industry. GIA argues that developing markets, especially India and China, will emerge as major agricultural and industrial biotechnology markets owing to rapid increase in population and income levels."
Full company reports can be found at www.paragonreport.com/INO and www.paragonreport.com/KERX.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Read the full article at PR-Inside.com.
ProActive Capital Indexes
See ProActive's Disclaimer
.png)
BillMyParents, Inc. (OTCQB: BMPI) (OTCBB: BMPI) offers the perfect solution for parents who want to help their teens develop smart spending habits. The BillMyParents SpendSmart Card is the only instantly track-able, reloadable MasterCard prepaid card that lets parents and teens track spending in real time. Features include the ability to instantly lock, unlock and reload the card at any time; text alerts to parents and teens showing real-time transaction details with each purchase; and the freedom and security of a MasterCard prepaid card without the risk of overdrafts, accruing debt or affecting credit scores. BillMyParents provides parents with a modern way to help teach their teens financial responsibility, when it counts.
The company has released a new Investor Overview for January 2012. Slides include Corporate Overview, Executive Team, Board of Directors, Market Overview, Product and Features, Building Brand and Sales Momentum, Financial Opportunity, Q & A, and more.
Corporate Overview:
- BillMyParents, Inc. (OTCBB: BMPI) provides payments solutions to teens, young adults and their parents
- The Company’s primary product offering is a prepaid reloadable MasterCard with parental features including monitoring, reloading remotely and lost money recovery
- Less expensive alternative to cash, credit or debit cards; no credit / overdraft fees and no bank account fees
- Subscription based revenue model with a monthly account maintenance fee in addition to card load fees and ATM access fees
- The prepaid card market is rapidly growing; expected to grow from $165 billion to over $421 billion in the next two years*
*Mercator Advisory Group
ProActive Capital Indexes
See ProActive's Disclaimer
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
An article from RTT News provides an in-depth look at Canadian drugmaker Aeterna Zentaris, the company that licensed the rights to Perifosine to Keryx BioPharmaceuticals for North America:
"Personalized medicine, which refers to tailoring treatments to a patient's specific condition, is a revolutionary concept in the field of healthcare, very different from the 'one-size-fits-all' approach to the diagnosis and treatment of disease. One of the companies pursuing this innovative approach of personalized medicine is Canadian drugmaker Aeterna Zentaris Inc. (AEZS: News) (AEZ.TO: News).
Aeterna is a late-stage drug development company specialized in oncology and endocrine therapy. The company has two drug candidates in phase III testing - Perifosine for advanced metastatic colorectal cancer and multiple myeloma, and AEZS-130, a diagnostic test for growth hormone deficiencies." Read more at RTTNews.com.
KRX-0401 (perifosine) is a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. The effects of KRX-0401 on Akt are of particular interest because of the importance of this pathway in the development of most cancers, with evidence that it is often activated in tumors that are resistant to other forms of anticancer therapy, and the difficulty encountered thus far in the discovery of drugs that will inhibit this pathway without causing excessive toxicity. High levels of activated Akt (pAkt) are seen frequently in many types of cancer and have been correlated with poor prognosis. Read more about perifosine at Keryx.com.
Keryx is currently awaiting results of its Phase III trial for perifosine for both refractory advanced colorectal cancer and multiple myeloma. In a short article on Seeking Alpha about Keryx's January 12 presentation at the JP Morgan's 30th Annual Healthcare Conference, contributor A.G.C.M pointed out that "if Perifosine results are positive it could spark a bidding war amongst big pharma companies looking to boost dwindling revenue due to patent expiration on blockbuster drugs." He went on to say that "Keryx stock could possibly return investors triple digit returns if the Phase III results are positive." Read more at Seeking Alpha.
ProActive Capital Indexes
See ProActive's Disclaimer
Premier Alliance Group (OTCBB: PIMO; Twitter: $PIMO) provides business consulting services and human capital solutions to customers with a focus on core areas of business processes used throughout the corporate world including project management, business analysis, business consulting and strategic consulting. Typical initiatives in which Premier provides services include compliance and regulatory, merger and acquisition, and business process reengineering efforts. Clients are serviced with Knowledge-Based expertise in 3 core practice areas:
Business Performance and Technology
PIMO partners with CFOs, CIOs and other executives to ensure that operational processes and activities align with enterprise goals in delivering maximum returns that contribute to bottom line performance. The focus is on sustainable solutions and measurable results. PIMO also works with clients to help them optimize the returns from their technology investments. Services include business process management and reengineering, expense and investment rationalization, information management and more.
Governance, Risk and Compliance
In helping clients address regulatory, risk and compliance issues, PIMO empowers them with a deeper understanding of risk as well as business insights that will contribute to enhanced performance down the road. Services include risk management, regulatory compliance, internal audit and business resilience.
Finance and Accounting
PIMO also provides a broad cross section of expertise, specializing in allowing clients to seamlessly manage critical finance efforts during periods of change. The PIMO team can assist clients with specific subject-matter expertise or the resources to facilitate broad projects spanning multiple finance and operations areas across your company. Services include project and interim delivery in SEC reporting, general and cost accounting, financial planning and analysis, and technical accounting.
ProActive Capital Indexes
See ProActive's Disclaimer
TapImmune Inc. (OTCBB: TPIV) is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected. The Company's vaccine has shown effective restoration of TAP which restores and augments the marker (antigen) presentation and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works as an adjuvant or 'accelerant' to enhance targeted vaccines against infectious diseases. Including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1000 times. The company is currently developing AdhTAP for the commencement of toxicology studies leading to the initiation of Phase I clinical trials. The global vaccine market is expected to grow from $13 billion in 2007 to $21 billion in 2010.
Glynn Wilson, Chairman and CEO of TapImmune, has provided a corporate update to current and future shareholders.
Highlights include:
- In November, Mark Reddish joined the company as Vice President of Product Development. Mark is a recognized leader in vaccine technology development with an impressive track record in taking leading immunotherapy products from early research through development, both in the areas of cancer vaccines and biodefense.
- In January, the company opened their new laboratories and offices at 1551 Eastlake Avenue in Seattle. The opening of these new facilities is consistent with the company’s strategy of managing costs using a small core internal team that leverages external resources.
- In August the FDA approved an IND (Investigational New Drug application) and the Company signed a sponsored research agreement with the Mayo Clinic for a Phase 1 Her2neu Breast Cancer Clinical Trial, which is scheduled to start in the first quarter of 2012. The trial will use a patented technology developed at the Mayo clinic. TapImmune has the exclusive Option to license this technology.
Read the full update at TapImmune.com.
Dr. Wilson concluded his update as follows:
"In 2011 we made significant progress with very few resources. Our recent progress and our build up of resources indicate that we will make even greater progress in 2012. On the technology and product pipeline side, I believe we are fundamentally strong and poised to be a leading company in a highly attractive and expanding market, a position reinforced by our recruitment of top-class managers, advisors and investors who all share our vision. I thank them all for their efforts.
It is clear that our share price has not yet caught up with our corporate and technology progress, but I believe that this will happen as we expand our activities and our progress becomes more widely known and understood."
ProActive Capital Indexes
See ProActive's Disclaimer
BillMyParents, Inc. (OTCQB: BMPI) (OTCBB: BMPI) offers the perfect solution for parents who want to help their teens develop smart spending habits. The BillMyParents SpendSmart Card is the only instantly track-able, reloadable MasterCard prepaid card that lets parents and teens track spending in real time. Features include the ability to instantly lock, unlock andreload the card at any time; text alerts to parents and teens showing real-time transaction details with each purchase; and the freedom and security of a MasterCard prepaid card without the risk of overdrafts, accruing debt or affecting credit scores. BillMyParents provides parents with a modern way to help teach their teens financial responsibility, when it counts.
The company has announced the appointment of Joe Proto as a new member of the Company's Board of Directors, effective January 25, 2012.
Mr. Proto is a seasoned and successful senior executive and entrepreneur with three decades in the billing and payments industry. He is currently the Chairman and Chief Executive Officer of electronic billing company Transactis Inc. Mr. Proto "founded REMITCO, a remittance processing company where he also served as President for 11 years, which was acquired in 2000 by First Data Corp. [He] also founded Financial Telesis (CashFlex), a payment processor to 65 of the top 100 banks in the U.S., which was acquired by CoreStates/Wachovia and is now a part of Wells Fargo. In 2004, Mr. Proto co-founded Windham Ventures, an investment company focusing on financial technology and life sciences companies, where he currently serves as a founding partner."
BillMyParents' Chairman and Chief Executive Officer Mike McCoy commented,
"We are honored to welcome Joe to our Board of Directors. He is deeply knowledgeable about the payments industry as well as the financial technology field. As one of the leading experts in the payment industry, we believe Mr. Proto will be an invaluable asset to BillMyParents."
BillMyParents also announced that Board member Mark Sandson is retiring from the Board, also effective January 25, 2012. Going forward, the company has engaged Mr. Sandson in a consulting role.
"The Board of Directors greatly appreciates Mr. Sandson's contributions, and expects to continue to benefit from his experience and insights," said Mike McCoy.
Read the full release at Yahoo Finance.
ProActive Capital Indexes
See ProActive's Disclaimer